BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Muscari F, Guinard JP, Kamar N, Peron JM, Otal P, Suc B. Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma. World J Surg. 2012;36:1824-1831. [PMID: 22532309 DOI: 10.1007/s00268-012-1587-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Muscari F, Maulat C. Preoperative alpha-fetoprotein (AFP) in hepatocellular carcinoma (HCC): is this 50-year biomarker still up-to-date? Transl Gastroenterol Hepatol 2020;5:46. [PMID: 33073041 DOI: 10.21037/tgh.2019.12.09] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ren X, Ji Y, Jiang X, Qi X. Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. Biosci Rep 2018;38:BSR20181423. [PMID: 30355653 DOI: 10.1042/BSR20181423] [Reference Citation Analysis]
3 Amado V, Rodríguez-Perálvarez M, Ferrín G, De la Mata M. Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria. J Hepatocell Carcinoma 2019;6:1-10. [PMID: 30613572 DOI: 10.2147/JHC.S174549] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2015; 7(3): 406-424 [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 68] [Cited by in F6Publishing: 62] [Article Influence: 9.7] [Reference Citation Analysis]
5 Grat M, Kornasiewicz O, Hołówko W, Lewandowski Z, Zieniewicz K, Paczek L, Krawczyk M. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45:1899-903. [PMID: 23769067 DOI: 10.1016/j.transproceed.2012.12.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
6 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016; 8(21): 881-890 [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
7 Burnett NP, Dunki-jacobs EM, Callender GG, Anderson RJ, Scoggins CR, Mcmasters KM, Martin RC. Evaluation of Alpha-fetoprotein Staging System for Hepatocellular Carcinoma in Noncirrhotic Patients. The American Surgeon 2013;79:716-22. [DOI: 10.1177/000313481307900717] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Kudo A, Matsumura S, Ban D, Irie T, Ochiai T, Tanaka S, Arii S, Tanabe M. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol Res 2014;44:E437-46. [PMID: 24690156 DOI: 10.1111/hepr.12335] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
9 Nakao K, Ichikawa T. Recent topics on α-fetoprotein. Hepatol Res. 2013;43:820-825. [PMID: 23347387 DOI: 10.1111/hepr.12052] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
10 Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016; 8(1): 58-68 [PMID: 26783421 DOI: 10.4254/wjh.v8.i1.58] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
11 Charriere B, Muscari F, Maulat C, Bournet B, Bonnet D, Bureau C, Otal P, Peron J, Suc B. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings: Treatment of Hepatocellular Carcinoma. J Surg Oncol 2017;115:330-6. [DOI: 10.1002/jso.24500] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
12 Chan SC, Sharr WW, Chok KS, Chan AC, Lo CM. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts. Transplantation. 2013;96:995-999. [PMID: 23924774 DOI: 10.1097/tp.0b013e3182a339a7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lei JY, Wang WT, Yan LN. Hangzhou criteria for liver transplantation in hepatocellular carcinoma: a single-center experience. European Journal of Gastroenterology & Hepatology 2014;26:200-4. [DOI: 10.1097/meg.0b013e3283652b66] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
14 Park ER, Kim SB, Lee JS, Kim YH, Lee DH, Cho EH, Park SH, Han CJ, Kim BY, Choi DW, Yoo YD, Yu A, Lee JW, Jang JJ, Park YN, Suh KS, Lee KH. The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma. Cancer Med 2017;6:749-60. [PMID: 28332314 DOI: 10.1002/cam4.1042] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]